Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans-Reference-Cited by-同舟云学术

Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans

Published:2018-06-13 Issue:10 Volume:74 Page:1281-1289
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Kim Kyoung-Ah,Park In-Bae,Park Ji-Young

Funder

Korea University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-018-2501-x/fulltext.html

Reference37 articles.

1. Roehrborn CG (2009) Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 11[Suppl 1]:S1–S8

2. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ (2002) Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 62(1):135–167

3. Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Wein M, Michel MC (2011) Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 72(2):247–256. https://doi.org/10.1111/j.1365-2125.2011.03988.x

4. Koiso K, Akaza H, Kikuchi K, Aoyagi K, Ohba S, Miyazaki M, Ito M, Sueyoshi T, Matsushima H, Kamimura H, Watanabe T, Higuchi S (1996) Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol 36(11):1029–1038

5. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD (2008) Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84(3):347–361. https://doi.org/10.1038/sj.clpt.6100482

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia;Pharmacy & Pharmacology;2024-05-08

2. Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia;Drug Metabolism and Personalized Therapy;2023-09-04

3. Фармакогенетические маркеры эффективности и безопасности лечения пациентов с симптомами нижних мочевыводящих путей при доброкачественной гиперплазии предстательной железы: результаты пилотного исследования;Pharmacogenetics and Pharmacogenomics;2023-04-03

4. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin to related CYP2D6*10 allele;ARCH PHARM RES;2021

5. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele;Archives of Pharmacal Research;2021-11